1-9 of 9
M Coleman
Close
Sort by
Journal Articles

Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.

Ruben Niesvizky, P.G. Richardson, P. Sonneveld, M.W. Schuster, M. Coleman, D. Irwin, E.A. Stadtmauer, T. Facon, J. Harousseau, A. Boral, K.C. Anderson
Journal: Blood
Blood (2006) 108 (11): 3529.
https://doi.org/10.1182/blood.V108.11.3529.3529
Published: 2006
Journal Articles

Lenalidomide Induced Myelosupression Is Potentially Associated with Renal Dysfunction in Treatment Naïve Myeloma (MM) Patients Receiving BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx).

Ruben Niesvizky, MD, D.S. Jayabalan, F. Zafar, P. Christos, R. Lent, MD, R. Pearse, MD,PhD, J. Tepler, MD, S. Ely, MD, T. Shore, MD, J. Harpel, MD, PhD, M. Schuster, MD, K. Pekle, J.B. Jalbrzikowski, H.J. Cho, MD,PhD, J. Leonard, MD, M. Mazumdar, S. Chen-Kiang, PhD, M. Coleman, MD
Journal: Blood
Blood (2006) 108 (11): 3549.
https://doi.org/10.1182/blood.V108.11.3549.3549
Published: 2006
Journal Articles

BiRD (Biaxin®/Revlimid®/Dexamethasone) Combination Therapy (Rx) Results in High Complete Remissions (CR) and Overall Responses in Myeloma (MM) with Poor Prognostic Features.

Ruben Niesvizky, MD, K. Pekle, RN, ANPC, U. Gelbshtein, F. Zafar, RPAC, S. Ostrow, MD, R. Pearse, MD, PhD, H. Cho, MD, PhD, J. Tepler, MD, S. Ely, MD, R. Lent, PhD, D. Jayabalan, T. Shore, MD, J. Harpel, MD, PhD, M. Schuster, MD, L. Lyons, R. Furman, MD, J. Leonard, MD, S. Chen-Kiang, PhD, M. Coleman, MD
Journal: Blood
Blood (2005) 106 (11): 642.
https://doi.org/10.1182/blood.V106.11.642.642
Published: 2005
Journal Articles

Dominant thalassemia-like phenotypes associated with mutations in exon 3 of the beta-globin gene

HH Jr Kazazian, CE Dowling, RL Hurwitz, M Coleman, A Stopeck, JG 3d Adams
Journal: Blood
Blood (1992) 79 (11): 3014–3018.
https://doi.org/10.1182/blood.V79.11.3014.3014
Published: 1992
Journal Articles

Restoration of responsiveness of chronic myeloid leukemia granulocyte- macrophage colony-forming cells to growth regulation in vitro following preincubation with prostaglandin E

LM Pelus, E Gold, S Saletan, M Coleman
Journal: Blood
Blood (1983) 62 (1): 158–165.
https://doi.org/10.1182/blood.V62.1.158.158
Published: 1983
Journal Articles

Immunologic abnormalities in myelofibrosis with activation of the complement system

BR Gordon, M Coleman, P Kohen, NK Day
Journal: Blood
Blood (1981) 58 (5): 904–910.
https://doi.org/10.1182/blood.V58.5.904.904
Published: 1981
Journal Articles

Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies

M Coleman, RT Silver, TF Pajak, F Cavalli, KR Rai, JE Kostinas, O Glidewell, JF Holland
Journal: Blood
Blood (1980) 55 (1): 29–36.
https://doi.org/10.1182/blood.V55.1.29.29
Published: 1980
Journal Articles

Improved survival of increased-risk myeloma patients on combined triple- alkylating-agent therapy: a study of the CALGB

JB Harley, TF Pajak, OR McIntyre, S Kochwa, MR Cooper, M Coleman, J Cuttner
Journal: Blood
Blood (1979) 54 (1): 13–22.
https://doi.org/10.1182/blood.V54.1.13.13
Published: 1979
Journal Articles

A clinical study of the lupus anticoagulant

MA Schleider, RL Nachman, EA Jaffe, M Coleman
Journal: Blood
Blood (1976) 48 (4): 499–509.
https://doi.org/10.1182/blood.V48.4.499.499
Published: 1976